Innova Biosciences launches kit for confirming successful antibody-biotin conjugation
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of the Biotin Check&Go! Kit, which sits alongside its recently launched Conjugate Check&Go! Kit and is the company’s second lateral flow product specific to antibody labeling.
Unpicking the links between dietary restriction and ageing
The effects of reduced food consumption and lifespan extension have been observed in many species, including primates, but the biology behind how this is achieved is poorly understood.
Innova Biosciences introduces Magnetic Conjugation Kit
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of its Magnetic Conjugation Kit, the newest addition to the company’s range of particle conjugation technologies.
New kit enables rapid generation of Eu bead conjugates for high sensitivity assays
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of its europium bead conjugation kit, the latest addition to its range of particle technologies.
Innova Biosciences introduces the Conjugate Check&Go! Kit
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of the Conjugate Check&Go! Kit, the company’s first lateral flow product specific to antibody labelling.
Bicycle Therapeutics announces partnership with AstraZeneca to develop bicyclic peptides
Bicycle Therapeutics, a Babraham-based biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) product platform, announced today that it has entered into a collaboration with AstraZeneca for the identification and development of bicyclic peptides (Bicycles®) for the treatment of respiratory, cardiovascular and metabolic diseases.
Over £500m investment made in life-science companies located at the Babraham Research Campus
The recent announcement from Kymab on the closing of $100M investment series ‘C’ funding brings the total amount of investment raised by companies located on the Babraham Research Campus over the past two years, to be in excess of £0.5 Billion.
New conference centre ('The Cambridge Building') opens soon at Babraham Research Campus
A new conference and social facilities building, to be named The Cambridge Building, has been completed by SDC Builders and handed over to Babraham Bioscience Technologies (BBT), the organisation that develops and manages the Babraham Research Campus.
Axiogenesis and Metrion Biosciences announce stem cell collaboration
Axiogenesis and Metrion Biosciences collaborate to develop human iPSC-derived cardiomyocytes and neurons for translational drug discovery.
Cambridge Epigenetix introduces whole genome integrated workflow for epigenetic analysis
New Cambridge Epigenetix workflow system includes reagents and bioinformatics tools to improve ease and accessibility of DNA modification analysis.
Innova Biosciences introduces AbPure Magnetic Purification system
Innova Biosciences, a specialist provider of bioconjugation products and services, has announced the launch of the AbPure™ Magnetic Purification system.
Metrion Biosciences joins CRACK IT ‘DRGNET’ human pain research consortium
Babraham-based Metrion Biosciences Ltd, the specialist ion-channel and drug discovery CRO, has entered into an agreement with a network of partners to evaluate the use of primary human dorsal root ganglion (hDRG) neurons in pain research.
Axol Bioscience and Metrion Biosciences announce research collaboration
Axol, the human cell culture specialists, join experts in ion channel research to study human iPSC-derived cardiomyocytes for drug discovery applications.
Innova Biosciences introduces InnovaCoat GOLD-Carboxyl nanoparticles
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced the launch of a carboxylated derivative of its unique InnovaCoat® GOLD 40 nm nanoparticles. The new product enables customers to quickly generate highly stable covalent gold-antibody conjugates at R&D and manufacturing scales.
Study shows Immbio's novel pneumococcal vaccine to be safe and immunogenic
Babraham-based ImmunoBiology Ltd (ImmBio), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, reports positive results from the First-in-Human study of its novel vaccine, PnuBioVax™, against the bacterial pathogen Streptococcus pneumoniae (NCT02572635).
Innova Biosciences expands UK facility and increases laboratory space
Innova Biosciences, a specialist provider of bioconjugation products and services, today announced it has expanded its UK footprint to enable the company to increase its laboratory space.
Metrion Biosciences and EU partners receive €2.2M Eurostars SME funding
Babraham-based Metrion Biosciences Ltd, the specialist ion channel contract research organisation (CRO), today announced it is leading a consortium in receipt of a €2.2 million funding award under the Eurostars SME programme.
PhoreMost and The Wistar Institute collaborate to identify new druggable targets
PhoreMost Ltd, a Babraham-based biopharmaceutical company focused on increasing the diversity and affordability of novel therapeutics, announced today that it has entered into an alliance with The Wistar Institute to identify and de-orphan novel targets in cancer, aging and the immune system.
Innova Biosciences appoints Steve Howell as Non-Executive Director
Innova Biosciences, a specialist provider of bioconjugation products and services, has announced the appointment of Professor Steve Howell to the Board of Directors.
Imperial breaks ground at new Babraham facility
Imperial College marked the start of construction of new facilities to support spin-out and scale-up companies with a ground-breaking ceremony this week.
ImmBio initiates first-in-human studies of its novel pneumococcal vaccine, PnuBioVax
ImmunoBiology Ltd (ImmBio), a biopharmaceutical company developing next generation anti-infective vaccines based on its proprietary ImmBioVax™ technology, today announces that it has initiated enrolment for a First-in-Human study of its novel vaccine (PnuBioVax™) against the bacterial pathogen Streptococcus pneumoniae.
Innova Biosciences introduces range of conjugated antibodies
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, announced today the launch of a range of conjugated antibodies. The unique range leverages Innova’s Lightning-Link® and InnovaCoat® bioconjugation technologies, to provide customers with antibodies conjugated to an extensive range of enzymes, fluorescent dyes and colloidal gold, for improved flexibility in…
Innova Biosciences and Mologic sign supply and licensing agreement
Innova Biosciences (Innova), a specialist provider of bioconjugation products and services, and Mologic, a specialist diagnostic development company and molecular reagent innovator, announced today the signing of a supply and licensing agreement for use of Innova’s Lightning-Link® and InnovaCoat® GOLD technologies as part of Mologic’s commercial assay development services and range of…
Dr Jane Osbourn joins Babraham Bioscience Technologies as new Non-Executive Director
Babraham Bioscience Technologies Ltd (BBT), which develops and manages the Babraham Research Campus, announced today that Dr Jane Osbourn, VP R&D and Site Leader of MedImmune in Cambridge, has joined the board as a non-executive director.
Rapid Biosensor moves into pneumonia diagnostic testing at Point-of-Care
Rapid Biosensor Systems Ltd (Babraham Research Campus, Cambridge) is developing a rapid test for bacterial pneumonia by adapting its successful TB Breathalyser product, which has been endorsed by Medics in India and Ethiopia after field trials on nearly 1,000 people.